Applied Protein Sciences and Biomodels to Boost Cancer Care

Applied Protein Sciences (APS) has entered into a strategic alliance with Biomodels.

This alliance allows speedier product development and helps the former to expand its pipeline to develop proprietary drugs for mucositis, proctitis and Inflammatory Bowel Disease (IBD).

APS expects to launch its clinical program later this year. Aman Johar, CEO, said, “This relationship allows us flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to leading scientists and researchers."